Obtained the exclusive license for the small interfering nucleic acid drug "GW906"

Fulian^® (China's first ARB+thiazide diuretic compund sustained-release anti-hypertensive new drug) was launched

Xinchaotuo (China's first innovative ARNi antihypertensive drug) was launched

Class 2 new drug Fulitan^® (Allisartan Isoproxil and Amlodipine Tablet) was launched.

Class 1 innovative drug Xinlitin (Fultagliptin Benzoate Tablet) was launched.

Set up in the Hetao Shenzhen–Hong Kong Science and Technology Innovation Cooperation Zone

SaExten^® (Vena Cava Filter System) was launched

Patent drug Enaro^® (Enarodustat Tablet) was launched

Xinfutai Pro^® (Teriparatide Injection) was launched.

Left Atrial Appendage Occlusion Device was launched

Ticagrelor Tablet 60mg (Taiyi^®), Cefuroxime Sodium for Injection (Xinlixin), Rivaroxaban Tablet, Benazepril Hydrochloride Tablet (Xindayi^®), and Lercanidipine Hydrochloride Tablet (Xindaping^®) have been selected in the National Centralized Drug Procurement program.

Olmesartan Medoxomil Tablet (Xindayue^®), Ticagrelor Tablet (Taiyi^®), DesloratadineTablet (Xinminting) and Pitavastatin Calcium Tablet (Xinliming^®) were selected in the National Centralized Drug Procurement program.

Rapamycin Drug-eluting Vertebral Artery Stent System (Maurora^®) obtained the "Medical Device Registration Certificate".

Agreement was signed with JT to obtain exclusive development, commercialization, and sublicensing rights of Enarodustat in the Chinese market.

Salubris' first biological product Recombinant Teriparatide for Injection (Xinfutai^®) was launched

Pitavastatin Calcium Tablet (Xinliming^®) was launched

Bivalirudin for Injection (Taijianing) obtained the EU GMP certificate

Allisartan Isoproxil Tablet (Xinlitan) won the 20th China Patent Gold Award.

Invested and acquired the Biovention,Inc.

On December 29, the CDE released the first batch of varieties that passed the consistency evaluation, and Clopidogrel Bisulfate Tablet (Taijia) 75mg became the first batch of medicine passing the generic drug consistency evaluation.

Allisartan Isoproxil Tablet (Xinlitan) was included in the National  Reimbursement Drug List.

Salubris Biotherapeutics, Inc. was established in the USA.

Salubris exclusively subsidized the "Whole-hearted Care" drug donation project for the full-course management of acute coronary syndrome (ACS) patients

Salubris acquired Alain Biotechnology (Beijing) Co., Ltd.

Clopidogrel Bisulfate Tablets (Taijia) won the 17th China Patent Gold Award.

Salubris acquired Shenzhen KYD Biomedical Technology Co., LTD

Salubris (Chengdu) Jinkai Biopharmaceutical Research and Development Base has joined Salubris

Salubris (Suzhou) Jinmeng Biopharmaceutical Production Base has joined Salubris

Clopidogrel Bisulfate Tablet (Taijia) obtained the EU GMP certificate.

Allisartan Isoproxil Tablet (Xinlitan) was awarded the title of "2013 Top 10 Blockbuster Prescription Drugs in China" at the 11th China Pharmaceutical Marketing Emerging Leaders Forum and the 2013 China Top Ten Blockbuster Prescription Drugs Selection Conference

Salubris (Pingshan) Biomedical and Pharmaceutical Preparation Industrialization Base was established.

Salubris (Daya Bay) Oral Preparation and Chemical APIs Base was established.

Salubris (Shandong) Pharmaceutical Intermediate and API Production Base was established.

Shenzhen Salubris Pharmaceuticals Co., Ltd. was successfully listed on Shenzhen Stock Exchange.

APIs Plant of Shenzhen Salubris Pharmaceuticals Co., Ltd. was established and put into production.

Clopidogrel Bisulfate Tablets (Taijia) and Desloratadine Tablets (Xinminting) were rated as national key new products in 2003.

The exclusive Clopidogrel Bisulfate Tablets（Taijia) has been put into production.

Pharmaceutical Plant of Shenzhen Salubris Pharmaceuticals Co., Ltd. was established and put into production.

The first product, Azithromycin Dispersible Tablet (Xindakang), was put into production.

On November 3, Shenzhen Salubris Pharmaceuticals Co., Ltd. was established.